- Home
- PLUG vs BEAM Comparison
PLUG vs BEAM Comparison
Compare PLUG & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUG
- BEAM
- Stock Information
- Founded
- PLUG 1997
- BEAM 2017
- Country
- PLUG United States
- BEAM United States
- Employees
- PLUG N/A
- BEAM N/A
- Industry
- PLUG Industrial Machinery/Components
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLUG Energy
- BEAM Health Care
- Exchange
- PLUG Nasdaq
- BEAM Nasdaq
- Market Cap
- PLUG 1.6B
- BEAM 1.6B
- IPO Year
- PLUG 1999
- BEAM 2020
- Fundamental
- Price
- PLUG $1.16
- BEAM $17.17
- Analyst Decision
- PLUG Hold
- BEAM Strong Buy
- Analyst Count
- PLUG 16
- BEAM 11
- Target Price
- PLUG $1.76
- BEAM $48.90
- AVG Volume (30 Days)
- PLUG 103.7M
- BEAM 1.8M
- Earning Date
- PLUG 08-07-2025
- BEAM 08-05-2025
- Dividend Yield
- PLUG N/A
- BEAM N/A
- EPS Growth
- PLUG N/A
- BEAM N/A
- EPS
- PLUG N/A
- BEAM N/A
- Revenue
- PLUG $642,224,000.00
- BEAM $63,578,000.00
- Revenue This Year
- PLUG $17.73
- BEAM N/A
- Revenue Next Year
- PLUG $26.15
- BEAM $8.82
- P/E Ratio
- PLUG N/A
- BEAM N/A
- Revenue Growth
- PLUG N/A
- BEAM N/A
- 52 Week Low
- PLUG $0.69
- BEAM $13.53
- 52 Week High
- PLUG $3.34
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- PLUG 54.26
- BEAM 48.68
- Support Level
- PLUG $1.09
- BEAM $16.11
- Resistance Level
- PLUG $1.27
- BEAM $17.38
- Average True Range (ATR)
- PLUG 0.16
- BEAM 1.02
- MACD
- PLUG -0.01
- BEAM 0.03
- Stochastic Oscillator
- PLUG 31.48
- BEAM 30.84
About PLUG Plug Power Inc.
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.